HKD 40.35
(3.59%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 7.71 Billion CNY | 5.81% |
2022 | 7.28 Billion CNY | 49.46% |
2021 | 4.87 Billion CNY | 50.48% |
2020 | 3.24 Billion CNY | 70.6% |
2019 | 1.89 Billion CNY | 46.99% |
2018 | 1.29 Billion CNY | -17.19% |
2017 | 1.56 Billion CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 7.4 Billion CNY | -4.02% |
2024 Q2 | 7.4 Billion CNY | 0.0% |
2023 Q1 | 7.7 Billion CNY | 5.69% |
2023 Q2 | 7.7 Billion CNY | 0.0% |
2023 Q4 | 7.71 Billion CNY | 2.43% |
2023 FY | 7.71 Billion CNY | 5.81% |
2023 Q3 | 7.52 Billion CNY | -2.27% |
2022 Q2 | 6.1 Billion CNY | 0.0% |
2022 Q4 | 7.28 Billion CNY | 0.0% |
2022 Q3 | 7.28 Billion CNY | 19.36% |
2022 FY | 7.28 Billion CNY | 49.46% |
2022 Q1 | 6.1 Billion CNY | 25.22% |
2021 Q1 | 4.05 Billion CNY | 25.27% |
2021 FY | 4.87 Billion CNY | 50.48% |
2021 Q4 | 4.87 Billion CNY | 0.0% |
2021 Q3 | 4.87 Billion CNY | 20.12% |
2021 Q2 | 4.05 Billion CNY | 0.0% |
2020 Q2 | 1.82 Billion CNY | 0.0% |
2020 FY | 3.24 Billion CNY | 70.6% |
2020 Q4 | 3.24 Billion CNY | 0.0% |
2020 Q3 | 3.24 Billion CNY | 77.26% |
2020 Q1 | 1.82 Billion CNY | -3.76% |
2019 FY | 1.89 Billion CNY | 46.99% |
2019 Q1 | 1.5 Billion CNY | 16.57% |
2019 Q4 | 1.89 Billion CNY | 0.0% |
2019 Q3 | 1.89 Billion CNY | 13.39% |
2019 Q2 | 1.67 Billion CNY | 11.2% |
2018 Q3 | 1.29 Billion CNY | 0.0% |
2018 FY | 1.29 Billion CNY | -17.19% |
2018 Q4 | 1.29 Billion CNY | 0.0% |
2018 Q1 | - CNY | 0.0% |
2017 FY | 1.56 Billion CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -4946.048% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | -9.253% |